11.06.2024

Affini-T Therapeutics to Present Trial-in-Progress Poster and Preclinical Data from Its Oncogenic Driver Programs Targeting TP53 R175H, KRAS G12D and KRAS-G12V at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Press Releases

05.28.2024

Affini-T Therapeutics Announces First Patient Dosed in KRAS G12V Phase 1 Program and Presentation of Trial-in-Progress Poster at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

Press Releases

05.01.2024

Affini-T Therapeutics to Present Data from Its Preclinical Programs Targeting KRAS G12D and TP53 R175H at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Press Releases

ENDPOINTS

06.02.2023

Exclusive: Affini-T taps Sanofi alum to lead hunt for partnerships; Alkermes locks in CEO for oncology spinout

News

ENDPOINTS

04.19.2023

KRAS, one of cancer’s toughest targets, sees a surge of new therapies trying to limit side effects: #AACR23

News

ENDPOINTS

11.28.2022

Endpoints’ 10 biggest stories of 2022

News

11.05.2024

T Cell Engagers Targeting HLA-A*11:01 KRAS-G12D and KRAS-G12V Mutations for Cancer Immunotherapy

Presentations

11.05.2024

A novel T cell engager targeting HLA-A*02:01 TP53-R175H for cancer immunotherapy

Presentations

11.05.2024

AFNT-211 A Phase I study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA­ A*ll:01-restricted, KRAS G12V-specific transgenic TCR; CD8α/β coreceptor; and FAS-41BB switch receptor in patients with advanced or metastatic solid tumors

Presentations